Highlights Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 14:30:19 14/05/2026 +04			5-day change	1st Jan Change
38.48 ^EUR	+1.36%		+2.83%	+4.00%

01:06pm	Bayer Kept at Buy as Mwb Notes 'Solid' Q1 Results	MT
09:40am	BAYER AG : JP Morgan maintains a Buy rating	ZD

Highlights

01:06pm	Bayer Kept at Buy as Mwb Notes 'Solid' Q1 Results	MT
05-13	Bayer Kept at Market Perform as BMO Notes One-time Seed Licensing Boost in Q1	MT
05-12	Bayer: An assuring quarter towards gradual transformation
05-12	Bayer surprises with robust agricultural performance as Glyphosate ruling looms	RE
05-12	Bayer Shares Climb After Earnings Beat Expectations	DJ
05-12	Bayer CEO remains confident in glyphosate dispute, awaits Supreme Court ruling	RE
05-12	JPMorgan maintains 'Overweight' rating on Bayer - Target 50 euros	DP
05-12	Bayer surprises to the upside on agricultural strength - shares rally sharply	DP
05-12	Germany's Bayer Logs Higher Q1 Net Income; Net Sales Down	MT
05-12	Bayer Reiterates 2026 Currency-adjusted Outlook as First-quarter Profit More Than Doubles	MT
05-12	Strong Agribusiness Performance Delivers Surprise Earnings Jump for Bayer	RE
05-12	Bayer Net Profit Surges Driven by Growth in Agricultural Division	DJ
05-12	Germany's Bayer Logs Higher Q1 Net Income; Net Sales Down	MT
05-12	Bayer Q1 operating profit jumps 9% on boost from soy business	RE
05-12	Bayer Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Bayer Announces Positive Topline Results from the Phase III REVEAL Study	CI
05-06	Bayer Bolsters Ophthalmology Pipeline with $2.45 Billion Perfuse Therapeutics Deal	MT
05-06	Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update	DJ
05-06	Bayer's experimental blood thinner cuts risk and severity of repeat strokes	RE
05-06	Bayer Bolsters Ophthalmology Pipeline with $2.45 Billion Perfuse Therapeutics Deal Bayer Bolsters Ophthalmology Pipeline with $2.45 Billion Perfuse Therapeutics Deal	MT
05-06	Bayer Aktiengesellschaft entered into an agreement to acquire Perfuse Therapeutics, Inc. for $2.5 billion.	CI
05-06	New study data bolsters Bayer's hopes for Asundexian	RE
05-06	Bayer to acquire Perfuse Therapeutics for deal valued up to $2.45 billion	RE
05-06	Bayer to Buy Perfuse Therapeutics in $2.45 Billion Deal	MT
05-06	Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal	RE